ENTITY
BeiGene

BeiGene (6160 HK)

439
Analysis
Health Care • China
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullish•BeOne
•16 Jan 2025 12:05•Broker

BeOne (ONC US) - Inflection Point Arrives: Operating Breakeven in 2025E

Targeting GAAP operating income breakeven in FY25. BeOne is on track to achieve GAAP operating income breakeven in FY25.

Logo
484 Views
Share
bullish•BeiGene
•17 Dec 2024 10:21

HK CEO & Director Dealings (17th Dec 2024): BeiGene, China Wantian, Super Hi Int'l/Haidilao

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.  These insights also flag those companies where...

Logo
376 Views
Share
•17 Mar 2025 07:30

China & HK Strategy: Who Are the Victims of a US Recession?

​Reliance on the US market varies among HK-listed companies, with some having high direct exposure to a recession. Those with low direct exposure...

Logo
496 Views
Share
bearish•Xiaomi
•21 Feb 2025 05:49

Hang Seng Indexes: Announcement Today; Updated Flows (Some Big Ones)

Hang Seng Indexes announces post market close today. There will be changes for the HSI, HSCEI, HSTECH, HSIII and HSCI indices. The net round-trip...

Logo
2.1k Views
Share
x